Endocrinology and Metabolism

Yeon-Kyung Choi

2 Articles

Miscellaneous
DN200434 Inhibits Vascular Smooth Muscle Cell Proliferation and Prevents Neointima Formation in Mice after Carotid Artery Ligation: Sudeep Kumar, Jonghwa Jin, Hyeon Young Park, Mi-Jin Kim, Jungwook Chin, Sungwoo Lee, Jina Kim, Jung-Guk Kim, Yeon-Kyung Choi, Keun-Gyu Park; Endocrinol Metab. 2022;37(5):800-809. Published online September 28, 2022; DOI: https://doi.org/10.3803/EnM.2022.1462

3,063 View
201 Download
1 Web of Science
1 Crossref

Background
Excessive proliferation and migration of vascular smooth muscle cells (VSMCs), which contributes to the development of occlusive vascular diseases, requires elevated mitochondrial oxidative phosphorylation to meet the increased requirements for energy and anabolic precursors. Therefore, therapeutic strategies based on blockade of mitochondrial oxidative phosphorylation are considered promising for treatment of occlusive vascular diseases. Here, we investigated whether DN200434, an orally available estrogen receptor-related gamma inverse agonist, inhibits proliferation and migration of VSMCs and neointima formation by suppressing mitochondrial oxidative phosphorylation.
Methods
VSMCs were isolated from the thoracic aortas of 4-week-old Sprague-Dawley rats. Oxidative phosphorylation and the cell cycle were analyzed in fetal bovine serum (FBS)- or platelet-derived growth factor (PDGF)-stimulated VSMCs using a Seahorse XF-24 analyzer and flow cytometry, respectively. A model of neointimal hyperplasia was generated by ligating the left common carotid artery in male C57BL/6J mice.
Results
DN200434 inhibited mitochondrial respiration and mammalian target of rapamycin complex 1 activity and consequently suppressed FBS- or PDGF-stimulated proliferation and migration of VSMCs and cell cycle progression. Furthermore, DN200434 reduced carotid artery ligation-induced neointima formation in mice.
Conclusion
Our data suggest that DN200434 is a therapeutic option to prevent the progression of atherosclerosis.

Citations

Citations to this article as recorded by

Jatrorrhizine inhibits Piezo1 activation and reduces vascular inflammation in endothelial cells
Tianying Hong, Xianmei Pan, Han Xu, Zhijuan Zheng, Lizhen Wen, Jing Li, Mingfeng Xia
Biomedicine & Pharmacotherapy.2023; 163: 114755. CrossRef

Diabetes, Obesity and Metabolism
Year-Long Trend in Glycated Hemoglobin Levels in Patients with Type 2 Diabetes during the COVID-19 Pandemic: Jonghwa Jin, Seong Wook Lee, Won-Ki Lee, Jae-Han Jeon, Jung-Guk Kim, In-Kyu Lee, Yeon-Kyung Choi, Keun-Gyu Park; Endocrinol Metab. 2021;36(5):1142-1146. Published online October 21, 2021; DOI: https://doi.org/10.3803/EnM.2021.1154

3,904 View
148 Download
4 Web of Science
5 Crossref

Abstract PDF Supplementary Material PubReader ePub

It has been suggested that the coronavirus disease 2019 (COVID-19) pandemic has had a negative impact on glycemic control in patients with type 2 diabetes mellitus (T2DM). However, no study has examined yearly trends in glycated hemoglobin (HbA1c) levels after the start of the COVID-19 outbreak. Here, we performed a retrospective analysis of HbA1c concentrations during the early period of the COVID-19 outbreak (COVID-19 cohort) and then compared the yearly trend in the mean HbA1c level, along with fluctuations in HbA1c levels, with those during previous years (non-COVID-19 cohorts). We observed that the mean HbA1c level in patients with T2DM increased during the first 6 months of the COVID-19 outbreak. After 6 months, HbA1c levels in the COVID-19 cohort returned to levels seen in the non-COVID-19 cohorts. The data suggest that vulnerable patients with T2DM should be monitored closely during the early period of a pandemic to ensure they receive appropriate care.

Citations

Citations to this article as recorded by

Physical and Mental Health Characteristics of Hospitalized COVID-19 Patients with and without Type 2 Diabetes Mellitus in Turkey
Abdulbari Bener, Murat Atmaca, Abdulla O. A. A. Al-Hamaq, Antonio Ventriglio
Brain Sciences.2024; 14(4): 377. CrossRef
A Hybrid Model of In-Person and Telemedicine Diabetes Education and Care for Management of Patients with Uncontrolled Type 2 Diabetes Mellitus: Findings and Implications from a Multicenter Prospective Study
Ayla M. Tourkmani, Turki J. Alharbi, Abdulaziz M. Bin Rsheed, Azzam F. Alotaibi, Mohammed S. Aleissa, Sultan Alotaibi, Amal S. Almutairi, Jancy Thomson, Ahlam S. Alshahrani, Hadil S. Alroyli, Hend M. Almutairi, Mashael A. Aladwani, Eman R. Alsheheri, Hyfa
Telemedicine Reports.2024; 5(1): 46. CrossRef
The indirect impact of the COVID-19 pandemic on people with type 2 diabetes mellitus and without COVID-19 infection: Systematic review and meta-analysis
Zhuoran Hu, Hin Moi Youn, Jianchao Quan, Lily Luk Siu Lee, Ivy Lynn Mak, Esther Yee Tak Yu, David Vai-Kiong Chao, Welchie Wai Kit Ko, Ian Chi Kei Wong, Gary Kui Kai Lau, Chak Sing Lau, Cindy Lo Kuen Lam, Eric Yuk Fai Wan
Primary Care Diabetes.2023; 17(3): 229. CrossRef
Evaluating Effects of Virtual Diabetes Group Visits in Community Health Centers During the COVID-19 Pandemic
Tracy Dinh, Erin M Staab, Daisy Nuñez, Mengqi Zhu, Wen Wan, Cynthia T Schaefer, Amanda Campbell, Michael Quinn, Arshiya A Baig
Journal of Patient Experience.2023;[Epub] CrossRef
Cardiovascular-related health behavior changes: lessons from the COVID-19 pandemic and post-pandemic challenges
Inha Jung, Won-Young Lee
Cardiovascular Prevention and Pharmacotherapy.2023; 5(4): 99. CrossRef

Author index